Synthetic Biologics, Inc Press Releases

SYN 
$1.64
*  
0.11
6.29%
Get SYN Alerts
*Delayed - data as of Sep. 22, 2014  -  Find a broker to begin trading SYN now
Exchange: AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day
9/16/2014 10:35:00 AM - PR Newswire

Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
9/12/2014 1:23:00 PM - PR Newswire

Synthetic Biologics to Host Phase II Trimesta™ for Multiple Sclerosis Conference Call
9/11/2014 6:58:00 AM - PR Newswire

Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day
9/10/2014 12:04:00 PM - PR Newswire

Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
9/8/2014 6:58:00 AM - PR Newswire

Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC
9/7/2014 8:58:00 AM - PR Newswire

Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
9/3/2014 6:58:00 AM - PR Newswire

Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections
9/2/2014 7:33:00 AM - PR Newswire

Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile
8/28/2014 6:56:00 AM - PR Newswire

Synthetic Biologics Announces Presentation of Poster for SYN-004 C. difficile Program at IDWeek 2014™
8/26/2014 6:58:00 AM - PR Newswire

Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
8/19/2014 6:56:00 AM - PR Newswire

Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
8/14/2014 6:58:00 AM - PR Newswire

Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day
8/13/2014 6:56:00 AM - PR Newswire

Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
8/12/2014 6:58:00 AM - PR Newswire

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
8/11/2014 8:00:00 AM - Business Wire

Synthetic Biologics to Report Second Quarter 2014 Financial Results
8/7/2014 6:56:00 AM - PR Newswire

Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
8/5/2014 6:58:00 AM - PR Newswire

Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta™ in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting
7/31/2014 6:57:00 AM - PR Newswire

Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
7/29/2014 1:28:00 PM - PR Newswire

Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
7/21/2014 6:58:00 AM - PR Newswire

Synthetic Biologics Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program
6/30/2014 6:57:00 AM - PR Newswire